A new phase 3 study (NCT05066217) will test the efficacy and safety of EPX-100 (Harmony Biosciences), a 1st generation antihistamine agent, as a potential treatment for patients with Lennox-Gastaut syndrome (LGS), a rare epileptic disorder. Overall, the study will enroll patients aged at least 2 years old with LGS who will be followed for a 20-week period, with optional open-label extension after the end of the maintenance phase.
Scott Baraban is the UCSF PI.